Analyst consensus rating
Rani Therapeutics Holdings Analyst Rating: Strong Buy
Direct answer
Rani Therapeutics Holdings's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.20.
Forecast evidence checked October 17, 2026.
Get free Rani Therapeutics Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.64
- Average price target
- $7.20
- High price target
- $11.00
- Low price target
- $5.00
- Low target gap
- +680.5%
- Target upside
- +1,023.9%
- High target gap
- +1,617.1%
- Target range width
- 936.6%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Rani Therapeutics Holdings?
Rani Therapeutics Holdings has a verified Strong Buy consensus. The same dataset has an average price target of $7.20.
How far are Rani Therapeutics Holdings's low and high targets from the recorded price?
The low target implies +680.5%, while the high target implies +1,617.1%.
How many analysts are included in Rani Therapeutics Holdings's consensus?
The verified consensus includes 5 analysts.
How is Rani Therapeutics Holdings's target upside or downside calculated?
The average target of $7.20 is divided by the recorded price of $0.64, then one is subtracted to produce +1,023.9%. This does not guarantee a future return.
When was Rani Therapeutics Holdings's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.